The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy (ABODE NAC)
At-home Breast Oncology Care Delivered With E-health Solutions - The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy
Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.
A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:
- Get personalized resources that can help them navigate through the stages of their treatment.
- Access vetted information about their cancer & treatment from a health library.
- Receive surveys about their health and well-being.
- Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
- Connect with a physiotherapist to discuss healthy living and wellness.
Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.
At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Tulin Cil
- Número de telefone: 3984 416-946-4507
- E-mail: tulin.cil@uhn.ca
Estude backup de contato
- Nome: Emma Reel
- Número de telefone: 647-202-1028
- E-mail: emma.reel@uhn.ca
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G2M9
- University Health Network
-
Contato:
- Tulin Cil, MD, MEd
- Número de telefone: 4169464507
- E-mail: tulin.cil@uhn.ca
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Females (assigned female at birth)*
- Diagnosed with primary invasive BC and receiving curative intent treatment
- Must have neoadjuvant chemotherapy as their first step in treatment
- Receiving systemic therapy at UHN
- Age≥18
- Access to an electronic device with connection to the internet
- A valid email address
- Can communicate in English
Exclusion Criteria:
- Males (assigned male at birth), as BC surgical treatment options and experiences are different
- Diagnosed with non-operable breast cancer
- Stage 4/metastatic (whether determined at diagnosis or during surgery)
- Those with hearing or visual challenges
- Should not be enrolled in any other UHN study using an e-Health application
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Sem intervenção: Control
Standard care |
|
|
Experimental: Intervention (App)
App + standard care |
The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Patient Activation Measure 13 (PAM-13)
Prazo: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Impact of Events Scale - Revised (IES-R)
Prazo: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
Generalized Anxiety Disorder 7 (GAD-7)
Prazo: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30
Prazo: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales). |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)
Prazo: 9 months post-baseline
|
A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information. |
9 months post-baseline
|
|
European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)
Prazo: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
A 42-item survey assessing quality of life specifically for breast cancer patients. The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems. |
Baseline 3 months post-baseline 3 months post-op 12 months post-baseline
|
|
Health Education Impact Questionnaire (heiQ)
Prazo: Baseline 9 months post-baseline
|
A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome. |
Baseline 9 months post-baseline
|
|
Clinical Evaluation Questionnaire -INS (CEQ-INS)
Prazo: 9 months post-baseline
|
A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team. |
9 months post-baseline
|
|
Health Service Outcomes - Wait Times
Prazo: Until 15 months post-baseline
|
The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals. |
Until 15 months post-baseline
|
|
Health Service Outcomes - Ambulatory Clinical Activity
Prazo: Until 15 months post-baseline
|
Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS). |
Until 15 months post-baseline
|
|
Health Service Outcomes - Discharge Information
Prazo: Until 15 months post-baseline
|
Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery. |
Until 15 months post-baseline
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 24-5369
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .